IQVIA has launched IQVIA Biotech and its new approach to providing clinical and commercial services for small biotech and biopharma companies. The solutions suite will provide simplified operating procedures, specialized teams, and services to help biopharma clients reach their drug development and commercialization milestones. IQVIA Biotech aims to deliver a transparent and streamlined process from initial planning to trial design and implementation to market launch and commercialization.
We designed this comprehensive solutions suite to address what our biotech customers were asking for — transparent and fit-for-purpose clinical processes with dedicated, therapeutically-aligned partners coupled with our unique set of enterprise capabilities. Those end-to-end capabilities include the analytics, technology and human capital clients need to smartly plan the launch and commercialization pre- and post-approval of their products, and the real world evidence needed to support pricing, safety, compliance, and regulatory requirements. We combine two decades of institutional experience specifically serving emerging biopharma companies with the power of the IQVIA CORE to focus on the immediate goals of our biotech customers
said chief executive officer
and chairman of IQVIA, Ari Bousbib.
IQVIA’s services incorporate real world evidence resources, advanced analytics, and transformative technology to help drive efficiencies. The company will leverage its deep therapeutic and scientific expertise to address specific needs at each milestone on the clinical development path and on the pre- and post-approval commercialization path. Key therapy areas for IQVIA Biotech include oncology, central nervous system, dermatology, cardiovascular, and immunology.
Biotech companies are advancing the drug development pipeline forward, and when they succeed, we all succeed. By launching IQVIA Biotech as the first-of-its kind global business, we can support biotech clients with local teams and our full suite of capabilities from molecule to market
said Richard Staub,
president, R&D Solutions at IQVIA.